Document is current

Article History

Received: 12 December 2022

Revised: 21 March 2023

Accepted: 23 March 2023

First Online: 14 April 2023

Competing interests

: ER, KK, IO, MM, SB, MB, and TS declare that they have no conflict of interest. DZ, PC, PS, AS, and JB report the following details of their affiliation or involvement with any organization or entity that has a financial or non-financial interest in the topic or material covered in this manuscript: DK reports personal fees for speaker honoraria from AstraZeneca, and Pfizer, personal fees for Advisory Board from Bristol-Myers Squibb, outside the submitted work. PC reports research fundings (institution) from Amgen, AstraZeneca, Boehringer, Novartis, Roche, Takeda and advisory boards and lecture fees (personal) from AstraZeneca, Boehringer, Chugai, Daiichi Sankyo, Gilead, Novartis, Pfizer, Roche, Takeda, outside the submitted work. PS reports personal fees for speaker honoraria from Incyte, Roche, Janssen, Novartis, AstraZeneca, Eisai, Leica, grants from Novartis, BMS, AstraZeneca, Illumina, Incyte, and boards from Incyte, Roche, AstraZeneca, BMS, MSD, Amgen, Janssen, Novartis, Bayer, Eisai, outside the submitted work. AS reports grants and personal fees from Bayer, BMS, grants from Chugai and personal fees from Astra Zeneca, MSD, Takeda, Seattle Genetics, Novartis, Illumina, Thermo Fisher, Eli Lily, Takeda, outside the submitted work. AS reports participation in Advisory Board/Speaker’s Bureau for Astra Zeneca, AGCT, Bayer, Bristol-Myers Squibb, Eli Lilly, Illumina, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda, and Thermo Fisher, grants from Bayer, Bristol-Myers Squibb, and Chugai, outside the submitted work. JB reports grants from German Cancer Aid and consulting from MSD, outside the submitted work.

: The study is based on publicly available data and did not require ethical approval.